Lotus Eye Hospital and Institute Limited

NSEI:LOTUSEYE Stock Report

Market Cap: ₹1.3b

Lotus Eye Hospital and Institute Management

Management criteria checks 4/4

Lotus Eye Hospital and Institute's CEO is Kuttapalayam Ramalingam, appointed in Aug 2020, has a tenure of 4.25 years. directly owns 1.43% of the company’s shares, worth ₹19.07M. The average tenure of the management team and the board of directors is 4.2 years and 3.8 years respectively.

Key information

Kuttapalayam Ramalingam

Chief executive officer

₹1.2m

Total compensation

CEO salary percentagen/a
CEO tenure4.3yrs
CEO ownership1.4%
Management average tenure4.2yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Aug 21
Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Jan 24
Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 08
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Jul 15
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

Apr 07
Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Oct 08
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 02
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

Jun 17
If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Mar 11
MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Dec 30
Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

Nov 20
Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Sep 21
The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Aug 27
Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Aug 03
Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

Jul 06
Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

CEO

Kuttapalayam Ramalingam (74 yo)

4.3yrs

Tenure

₹1,200,000

Compensation

Dr. Kuttapalayam Songappan Ramalingam, M.D., serves as an Executive Director at Lotus Eye Hospital and Institute Limited since February 10, 2021. Dr. Ramalingam serves as Chief Executive Officer at Lotus E...


Leadership Team

NamePositionTenureCompensationOwnership
Kuttapalayam Ramalingam
CEO & Executive Director4.3yrs₹1.20m1.43%
₹ 19.1m
Ramanujam Reghunathan
Chief Financial Officer2.5yrs₹1.70mno data
Mohanmenon Menon
Company Secretary & Compliance Officer2.8yrs₹1.08mno data
Sangeetha Sundaramoorthy
MD & Director4.2yrs₹3.09m18.84%
₹ 250.4m
Rajkumar Sundaramoorthy
Vice President of Administration6.5yrsno data0%
₹ 0

4.2yrs

Average Tenure

67yo

Average Age

Experienced Management: LOTUSEYE's management team is considered experienced (4.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kuttapalayam Ramalingam
CEO & Executive Director3.8yrs₹1.20m1.43%
₹ 19.1m
Sangeetha Sundaramoorthy
MD & Director5yrs₹3.09m18.84%
₹ 250.4m
Rajkumar Sundaramoorthy
Vice President of Administration4.8yrsno data0%
₹ 0
Kavetha Sundaramoorthy
Chairman of the Board8.5yrs₹150.00k18.78%
₹ 249.6m
Sengodagounder Natesan
Independent Director3.8yrs₹200.00kno data
Gopalakrishnan Veeramani
Independent Non-Executive Director1.9yrs₹200.00kno data
Perumalsamy Mahendran
Independent Non-Executive Director1.8yrs₹175.00kno data

3.8yrs

Average Tenure

61yo

Average Age

Experienced Board: LOTUSEYE's board of directors are considered experienced (3.8 years average tenure).